FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGE	S IN BENEFICI	AL OWNERSHIP

l	OIVID AFF	OIVID APPROVAL										
	OMB Number:	3235-0287										
ı	Estimated average	b. wdo o										

hours per response:

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Wingrove Theresa				2. Issuer Name and Ticker or Trading Symbol IMMUNOGEN INC [IMGN]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
wingro	ove There	<u>sa</u>		-		01100		1110	J., 1				Director		10% Ov		
-												x	Officer (below)	give title	Other (s below)	pecify	
(Last)	(F	First)	(Middle)				Trans	saction (Mont	n/Day/Year)				VP of Regulatory Affairs				
C/O IMMUNOGEN, INC.					02/15/2018							VP of Regulatory Arrairs					
830 WIN	TER STRE	EET		L													
					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Inc	6. Individual or Joint/Group Filing (Check Applicable				
(Street)												Line)					
WALTH	AM M	1A	02451									X	Form file	ed by One Re	porting Persor		
													Form file Person	ed by More th	an One Repor	ing	
(City)	(0	State)	(Zip)										reisuii				
(City)	(3	olale)	(Zip)														
		Ta	ble I - Non-D	erivati	ive S	ecuritie	s Ac	cquired, D	isposed	of, or	Bene	eficially	Owned				
Date			t. Transaction Date Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Yea		Code (Instr.		(A) or 3, 4 and 5)	Beneficial	Form (D) or	m: Direct or Indirect	7. Nature of ndirect				
							ar) 8)					Owned Fo	, , , ,		Ownership Instr. 4)		
								Code V	Amount		(A) or (D)	Price	Transactio				
			Table II - Dei	ivativ	e Sec	curities	Acc	uired, Dis	posed o	or B	enefi	icially C	wned	'	<u>'</u>		
								s, options									
1. Title of Derivative Security (Instr. 3)	Conversion Date Executor Exercise (Month/Day/Year) if any		3A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		of Se Unde Deriv	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
												Amount		(Instr. 4)	"		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	l N	or Number of Shares					
Stock option	\$10.65	02/15/2018		A		160,000		02/15/2019 ⁽¹⁾	02/15/2028	Comi		160,000	\$10.65	160,000	D		
(right to buy)										sto	CK						

Explanation of Responses:

 $1.\ Exercisable\ in\ three\ equal\ installments\ over\ the\ next\ three\ years\ starting\ on\ the\ first\ year\ anniversary\ of\ the\ grant.$

/s/ Craig Barrows, attorney in

<u>fact</u>

** Signature of Reporting Person

Date

02/20/2018

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.